Analytical issues in HPLC/MS/MS simultaneous assay of furosemide, spironolactone and canrenone in human plasma samples

Journal of Pharmaceutical and Biomedical Analysis

Volumn 52, Issue 5, 2010, Pages 734-740

  Sora, Daniela Iuliana ^a   Udrescu, Ştefan ^a   Albu, Florin ^a   David, Victor ^b   Medvedovici, Andrei ^a,b  

^a Bioanalytical Laboratory   (Romania)

^b UNIVERSITY OF BUCHAREST   (Romania)

Author keywords

Bioequivalence; Canrenone; ESI; Furosemide; HPLC; Method development; Method validation; Plasma samples; Spironolactone; Tandem MS detection

Indexed keywords

CANRENONE; FORMIC ACID; FUROSEMIDE; INDAPAMIDE; METHANOL; NITRAZEPAM; SILICA GEL; SPIRONOLACTONE;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CHROMATOGRAPHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; ELECTROSPRAY; FEMALE; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRECIPITATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSED PHASE LIQUID CHROMATOGRAPHY; SENSITIVITY ANALYSIS; TANDEM MASS SPECTROMETRY; THERMOSTABILITY; VALIDATION PROCESS;

CANRENONE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FUROSEMIDE; HUMANS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPIRONOLACTONE; TANDEM MASS SPECTROMETRY;

EID: 77950857572     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.03.004     Document Type: Article

References (31)

1. Espinosa Bosch M., Ruiz Sánchez A.J., Sánchez Rojas F., Bosch Ojeda C. Recent developments in analytical determination of furosemide. J. Pharm. Biomed. Anal. 2008, 48:519-532.
2. Walshe M., Kelly M.T., Smyth M.R. Comparison of two extraction methods for determination of propranolol and furosemide in human plasma by mixed-mode chromatography. J. Pharm. Biomed. Anal. 1996, 14:475-481.
3. Jankowski A., Skorek-Jankowska A., Lamparczyk H. Determination of pharmaco-kinetics of furosemide-amiloride drug combination. J. Chromatogr. B 1997, 693:383-391.
4. Gomez C., von Plessing C., Godoy C.G., Reinbach R., Godoy R. Method validation for the determination of furosemide in plasma by liquid-liquid extraction and high-performance liquid chromatography with fluorescence detection. J. Chilean Chem. Soc. 2005, 50:479-480.
5. Wenk M., Haegeli L., Brunner H., Krähenbühl S. Determination of furosemide in plasma and urine using monolithic silica rod liquid chromatography. J. Pharm. Biomed. Anal. 2006, 41:1367-1370.
6. Vallee F., Couture J., Pellerin B., LeBel M., Fast D., Schnell D. Quantitative determination of furosemide in human plasma by LC/MS/MS. AAPS Pharm. Sci. J. 1999, 11-S1:416.
7. Abdel-Hamid M.E. High-performance liquid chromatography-mass spectrometric analysis of furosemide in plasma and its use in pharmacokinetic studies. Farmaco 2000, 55:448-454.
8. Zendelovska D., Stafilov T. Sample preparation and RPHPLC determination of diuretics in human body fluids. Acta Pharm. 2006, 56:115-142.
9. Dong H., Xu F., Zhang Z., Tian Y., Chen Y. Simultaneous determination of spironolactone and its active metabolite canrenone in human plasma by HPLC-APCI-MS. J. Mass Spectrom. 2006, 41:477-486.
10. Sandall J.M., Millership J.S., Collier P.S., McElnay J.C. Development and validation of an HPLC method for the determination of spironolactone and its metabolites in paediatric plasma samples. J. Chromatogr. B 2006, 839:36-44.
11. Schütz W., Freissmuth M., Tuisl E., Blöchl-Daum B., Eichler H.G., Loew D. Bioequivalence between two furosemide-spironolactone formulations: a pharmacokinetic and pharmacodynamic approach. Curr. Med. Res. Opin. 1991, 12:450-458.
12. Vergin H., Mahr G., Metz R., Eichinger A., Nitsche V. Investigation on the bioequivalence of 2 oral preparations containing spironolactone and furosemide. Int. J. Clin Pharmacol. Ther. 1998, 36:231-238.
13. Abou-Auda H.S. Comparative pharmacokinetics and pharmacodynamics of furosemide in Middle Eastern and in Asian subjects. Int. J. Clin. Pharmacol. Ther. 1998, 36:275-281.
14. Cuadrado A., Rodríguez-Gascón A., Hernández R.M., Castilla A.M., de la Maza A., Yánez C., López de Ocáriz A., Solinís M.A., Pedraz J.L. In vivo pharmacokinetic-pharmacodynamic relationship and in vitro equivalence of two oral furosemide tablet formulations. Arzneim. Forsch. 2003, 53:321-329.
15. Najib N., Idkaidek N., Beshtawi M., Bader M., Admour I., Alam S.M., Zaman Q., Dham R. Bioequivalence evaluation of two brands of furosemide 40mg tablets (Salurin and Lasix) in healthy human volunteers. Biopharm. Drug Dispos. 2003, 24:245-249.
16. Sanchez M., Gomez C., Carrasco J., Ocana J., von Plessing C., Godoy C., Reinbach R., Godoy R. Evaluating average bioequivalence using methods for high variability drugs: a case study. Int. J. Clin. Pharmacol. Ther. 2008, 46:527-537.
17. Xu F.G., Zhang Z.J., Dong H.J., Tian Y., Liu Y., Chen Y. Bioequivalence assessment of two formulations of spironolactone in Chinese healthy male volunteers. Arzneim. Forsch. 2008, 58:117-121.
18. Srinivas N.R. Dodging matrix effects in liquid chromatography tandem mass spectrometric assays-compilation of key learnings and perspectives. Biomed. Chromatogr. 2009, 23:451-454.
19. Matuszewski B.K., Constanzer M.L. C.M. Chavez-Eng, matrix effect in quantitative LC/MS/MS analyses of biological fluids: a method for determination of finasteride in human plasma at picogram per milliliter concentrations. Anal. Chem. 1998, 70:882-889.
20. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 2003, 75:3019-3030.
21. Schuhmache J., Zimmer D., Tesche F., Pickard V. Matrix effects during analysis of plasma samples by electrospray and atmospheric pressure chemical ionization mass spectrometry: practical approaches to their elimination. Rapid Commun. Mass Spectrom. 2003, 17:1950-1957.
22. ICH topic Q2B, Note for guidance on validation of analytical procedures: methodology, (CPMP/ICH/281/95), ICH Technical Coordination, London, UK, 1996.
23. ICH topic Q2R1, Note for guidance on validation of analytical procedures: text and methodology, (CPMP/ICH/381/95), ICH Technical Coordination, London, UK, 1996.
24. Liteanu C., Rica I. Statistical Theory and Methodology of Trace Analysis, Chapter 6 - Detection Theory of Analytical Signals 1980, Ellis Horwood, Chichester, p. 165.
25. Guidance for Industry, Bioanalytical Method Validation. U.S. Department of Health and Human Services, FDA, CDER, CVM, 2001.
26. Waller E.S., Masarella J.W., Tomkiw M.S., Smith R.S., Doluisio J.T. Pharmacokinetics of furosemide after three different oral doses. Biopharm. Drug Dispos. 2006, 6:109-117.
27. Klauser E.A., Lavy E., Stepensky D., Cserepes E., Barta M., Friedman M., Hoffman A. Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers. J. Clin. Pharmacol. 2003, 43:711-720.
28. Ponto L.L., Schoenwald R.D. Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (part 1). Clin. Pharmacokinet. 1990, 18:381-408.
29. Ponto L.L., Schoenwald R.D. Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (part 2). Clin. Pharmacokinet. 1990, 18:460-471.
30. Nijkerk A.J., Vermeer J.M., Imanse M., De Vos D. The bioavailability of two new preparations of spironolactone tablets. Pharm. World Sci. 1983, 5:210-212.
31. Saudan P., Mach F., Perneger T., Schnetzler B., Stoermann C., Fumeaux Z., Rossier M., Martin P.-Y. Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol. Dial. Transplant. 2003, 18:2359-2363.